Surmodics to Participate in Upcoming Investor Conferences in March and April

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that management will participate in the following upcoming investor conferences:

The 34th Annual Oppenheimer Healthcare Conference, which is being held virtually from March 12-13, 2024.

• Management will present on Wednesday, March 13, at 2:00 p.m. Eastern Time.

The 23rd Annual Needham Healthcare Conference, which is being held virtually from April 8-11, 2024.

• Management will participate in a fireside chat on Tuesday, April 9, at 3:00 p.m. Eastern Time.

To access live webcasts of the presentations, go to “Events & Presentations” under the “Investors” section of the Company’s website at https://surmodics.gcs-web.com/events-and-presentations, and click on the webcast icon under “Upcoming Events.” Replays of the webcasts will be archived on the website for the following 90 days.

About Surmodics, Inc.

Surmodics is a leading provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. Surmodics also develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. This key growth strategy leverages the combination of the Company’s expertise in proprietary surface modification and drug-delivery coating technologies, along with its device design, development, and manufacturing capabilities. The Company’s mission is to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota. For more information, visit www.surmodics.com. The content of Surmodics’ website is not part of this press release or part of any filings that the company makes with the Securities and Exchange Commission.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240227712577/en/